Business Wire

OR-NIKE

11.3.2019 17:43:09 CET | Business Wire | Press release

Share
Nike Deepens Its Commitment to the Next Generation of Female Athletes, Kicking Off with the Upcoming Summer of Football

Today, more than 28 of the world’s top female footballers joined Nike (NYSE:NKE) in Paris to unveil 14 National Team Collections for this summer’s tournament in France. Record-breaking gymnast Simone Biles, champion fencer Ibtihaj Muhammad, two-time Grand Slam winner Li Na and other elite athletes also joined Nike in highlighting new partnerships to champion women and girls in sport.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005652/en/

“We believe this summer can be another turning point for the growth of women’s football,” said NIKE, Inc. Chairman, President and CEO Mark Parker. “And our bigger ambition is for that energy and participation to extend into all sports. Nike’s commitment is to continue our leading support of competitive athletes, invest in the next generation at the grassroots level and deliver more innovative and compelling product design for women.”

At the historic Palais Brongniart, Nike revealed an array of future-forward women’s innovation. Design for the 14 National Team Kits began with gathering detailed input on fit from professional footballers, followed by 4D scanning and motion capture in the Nike Sports Research Lab. Echoing this focus on women’s-specific precision engineering is Nike’s Spring/Summer 2019 high-performance bra collection, which was also on display at the event. Beyond innovations in fit, the National Team Kits reflect Nike’s continued commitment to being the world’s most sustainable sports brand, with each 2019 Nike Kit constructed from at least 12 recycled plastic bottles. Since 2010, Nike has diverted more than 6 billion plastic bottles from landfills through sustainable product design.

At the event, Nike also announced a new three-year partnership with UEFA Women’s Football, building on its support of elite footballers from North America to China, and its support of standout female athletes worldwide. In basketball, Nike is partnering with the WNBA, FIBA and the Chinese Basketball Association to grow the women’s game. Meanwhile, at the collegiate level, Nike is partnering with more than 200 universities across the U.S. to support more than 25,000 top female athletes across multiple sports.

At the grassroots level, Nike is addressing barriers to girls’ participation in sport through new community partnerships and access to products to help girls play with confidence. In Paris, Nike is partnering with Sport dans la Ville to train female coaches and engage girls through sports ranging from football and boxing to tennis and dance. Globally, Nike is collaborating with Women Win and Gurls Talk to support rising female coaches who are inspiring the next generation of girls to be active. And from London to Los Angeles, and Beijing to Buenos Aires, Nike is piloting a program to provide products such as the Nike Pro Hijab and Nike Classic Sports Bra to girls in need through schools and community partners worldwide.

Inspiration for these partnerships comes from female athletes who embody strength, power, and the heart and soul of Nike. Throughout 2019, Nike will honor female champions and changemakers with the next phase of its “Just Do It” campaign, which has inspired millions of athletes to chase their crazy dreams. This year, Nike’s campaign shines a spotlight on women around the world who have broken barriers, revolutionized sport and helped level the playing field for all. Click here to view the newest chapters in Nike’s “Just Do It” film series, launching this year in key cities across the globe.

About NIKE, Inc.

NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Hurley, which designs, markets and distributes surf and youth lifestyle footwear, apparel and accessories. For more information, Nike’s earnings releases and other financial information are available at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @Nike.

For more information, including multi-media materials, please visit: http://news.nike.com/

Contact:

Media Contact Mark Rhodes (503) 532-8877

Investor Contact Nitesh Sharan (503) 532-2828

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye